Evidence map›Paper›PMID 42547698›Full record

ReviewApplied biochemistry and biotechnology2026

Neural Stem Cells in Multiple Sclerosis: A Comprehensive Review of Preclinical and Clinical Evidence for CNS Repair and Translational Hurdles.

Elham Razzaghi, Arezo Azari, Ali Golchin, Aynaz Mihanfar

Abstract readReview
PubMed Publisher
In one paragraph

Review in Applied biochemistry and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Elham RazzaghiDepartment of Clinical Biochemistry, Faculty of Medicine, Urmia University of Medical Sciences, Urmia, Iran.
Arezo AzariSchool of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran.
Ali GolchinSkin and Stem Cell Research Center, Tehran University of Medical Sciences, Tehran, Iran. agolchin.vet10@yahoo.com.ORCID http://orcid.org/0000-0001-8661-5046
Aynaz MihanfarDepartment of Clinical Biochemistry, Faculty of Medicine, Urmia University of Medical Sciences, Urmia, Iran. ainazmihanfar2013@gmail.com.

Funding

Urmia University of Medical Sciences Urmia University of Medical Sciences
6 · The paper itself

Abstract

Multiple sclerosis (MS) is a chronic, immune-mediated, neurodegenerative disease of the central nervous system (CNS) characterized by inflammation, demyelination, and axonal destruction. MS impacts about 2.6 million individuals worldwide, typically presenting a wide array of clinical manifestations, such as motor, sensory, visual, and dementia, often leading to progressive disability. This progressive condition and the accumulation of handicaps draw attention to a crucial unmet need for therapies able to preserve neurons, encourage myelin regeneration, and restore neurological function. Although present conventional treatments mostly target the inflammatory aspects of MS, their effectiveness in treating the underlying neurodegeneration and supporting central nervous system repair is still limited. Recently, stem cell-based therapy and regenerative medicine have become some of the most promising approaches for treating MS. However, progress is subject to challenges and achievements are limited. The current study thoroughly investigates the findings of preclinical and clinical studies on neural stem cell (NSC)-based therapies for MS and highlights the related challenges. Study investigates its possible modes of action, treatment effectiveness, major earlier challenges, and emerging questions in transferring NSC-based therapies into clinical practice, aiming to improve neuroprotection, promote remyelination, and facilitate the repair of damaged CNS tissue. NSC-based therapies hold great potential as a regenerative therapy for MS, however, fundamental questions remain about the optimal delivery, long-term survival, functional integration, and potential immunological responses. To sum up, NSC-based therapies represent a promising new frontier in the next generation of treatments for MS. However, further comprehensive studies are required to conclusively confirm their safety, effectiveness, and long-term advantages.

Indexed as

Central nervous systemMultiple sclerosisNeural stem cellsNeurodegenerative diseasesRegenerative medicineRemyelination

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.